Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Similar studies in Swedish Mutation of APP
2023-11-22

Similar studies in Swedish Mutation of APP AD transgenic mice revealed reduced dynamin 1, AP180, and synaptophysin expression in the hippocampus, particularly prominent in the CA1 and CA4 subfields [19]. These findings imply that Aβ can act not only as a modulator of exocytosis but is a potent regul
-
br Introduction Quenchbody Q body immunoassay is a novel
2023-11-22

Introduction Quenchbody (Q-body) immunoassay is a novel biosensing technology that uses the quenching of fluorescence by intrinsic tryptophan (Trp) residues in antibody variable regions when dye(s) are conjugated to an antibody or antibody fragments in appropriate position, and de-quenching while
-
Lorlatinib is an orally active brain penetrant cyclic
2023-11-22

Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F
-
Butyrolactone 3 In our study the expression levels of adipon
2023-11-21

In our study, the expression levels of adiponectin and its receptors in the uteri, conceptuses, and throphoblasts were determined by the stage of early pregnancy. Therefore, it could be hypothesized that the adiponectin system is regulated by the local hormonal milieu. Hormonal regulation in the ute
-
Fig A shows a schematic representation of histological resul
2023-11-21

Fig. 2A shows a schematic representation of histological results according to the Franklin and Paxinos Mouse Brain Atlas (2001). The black circles represent the sites of drug infusion that were on-target within the amygdala. Gray circles represent the animals that had infusion locations outside the
-
GMF was later localized to
2023-11-21

GMFβ was later localized to the cytosol of primary astrocytes and glioma cell lines [67], prompting investigations into its involvement in intracellular signaling. It was found that PKA phosphorylation of GMFβ inhibits the ERK1/2 branch of the MAP kinase pathway [73], yet activates the stress-respon
-
In the olfactory bulb expression
2023-11-21

In the olfactory bulb, expression was especially prominent in the mitral cell layer from embryonic stages to adult tissues (Figs. 1D–G). By E14–E16, Ack1 signal was remarkably intense in the proliferative ventricular zone (Fig. 1D). From E18 to adult, expression was also observed in glomerular and g
-
In addition to the data
2023-11-21

In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr
-
Cyclophosphamide Autotaxin has been linked to chemoresistanc
2023-11-21

Autotaxin has been linked to chemoresistance through its ability to inhibit apoptosis induced by paclitaxel in breast cancer Cyclophosphamide [15] and LPA can inhibit cell death induced by cisplatin [40]. Autotaxin was included in the present study because it was identified as being over-expressed i
-
Introduction Lipoxygenases LOXs are key
2023-11-21

Introduction Lipoxygenases (LOXs) are key enzymes that catalyze the polyunsaturated fatty acids (PUFAs) such as arachidic Celastrol (AA), linoleic acid (LA) and others unsaturated fatty acids (Brash, 1999). LOXs are expressed in immune, neural, epithelial, tumor cells and other cells (Claesson, 20
-
br Experimental Procedures br Acknowledgments This work was
2023-11-21

Experimental Procedures Acknowledgments This work was supported by NIH/National Human Genome Research Institute (NHGRI)R00 HG006922 and NIH/NHGRIR01 HG008974 (to J.G.), the Huntsman Cancer Institute, and the Women’s Cancers Disease-Oriented Team at the Huntsman Cancer Institute. Research repor
-
Molecular docking quantitative structure activity
2023-11-21

Molecular docking, quantitative structure–activity relationship (QSAR) and high-throughput virtual screening (HTVS) studies have a very widespread use in computer-assisted drug design.25, 26, 27, 28 Suvannang et al. used the published X-ray crystallographic data to examine known aromatase inhibitors
-
The neural circuitry involved in the production of the
2023-11-21

The neural circuitry involved in the production of the EOD, its modulations, and in the sensory processing of communication signals has been well characterized (Bell and Maler, 2005; Chacron et al., 2011; Krahe and Maler, 2014; reviewed in Metzner, 1999). Pacemaker cells located in the pacemaker nuc
-
It is noticed that MDL
2023-11-21

It is noticed that MDL-28170 only partly reversed isoflurane-induced AIF release and nuclear translocation. In addition to calpain mechanism, activation of the DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP-1) is also essential for AIF release (Culmsee et al., 2005; Moubarak et al., 2007), a
-
VEGFR inhibition using sunitinib does not result in
2023-11-21

VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons
15655 records 241/1044 page Previous Next First page 上5页 241242243244245 下5页 Last page